Beacon Equity Featured Company: Advanced Viral Research Corp. (ADVR.OB)
Advanced Viral Research Corp. (ADVR.OB) is a biopharmaceutical company focused on improving the lives of patients by researching, developing and marketing innovative therapies for a range of serious disorders and diseases. The company is primarily committed to bringing its flagship product, AVR118, to patients. AVR118 appears to have the potential to stimulate the pro-inflammatory response needed to fight viral infections, including HIV, as well as reduce aberrant autoimmune-type inflammatory responses. In January of 2005, Advanced Viral Research Corp. reported the results from its Phase I/II clinical trial of AVR118 in patients with AIDS. The results demonstrated that the product has continued…